Target intelligence / Profile preview

Immunoglobulin kappa joining 1 (IGKJ1)

Target
IGKJ1
Molecular classification
Other (immunoglobulin joining region segment)
01

Overview

Immunoglobulin kappa joining 1 (IGKJ1) is a gene segment located on chromosome 2p11.2, encoding the J region of the variable domain of immunoglobulin kappa light chains[3][4][5]. During B cell development, IGKJ1 participates in V-(D)-J recombination, contributing to the diversity of antibody antigen recognition sites[1][2][3]. As part of the immunoglobulin kappa locus, it helps form the junction between the variable and constant regions of the kappa light chain. IGKJ1 is not a protein that acts as a classical receptor, enzyme, or transporter; it is one of several joining segments involved in generating the mature immunoglobulin kappa light chain. The functional product is incorporated into the antigen-binding portion of antibodies but is not itself a direct target for pharmacological intervention[1][3][5].

Other names
IGKJ1J1Immunoglobulin kappa joining 1
02

Mechanism of action

Not applicable. Drugs do not target IGKJ1 directly.

03

Biological functions

Assembly of antigen recognition site on immunoglobulin kappa light chainsParticipates in adaptive immune responseV-(D)-J recombination in B cell development (enables antigen binding site diversity)
04

Disease associations

Other. Indirect role only—involvement in immunoglobulin gene rearrangement dysregulation can feature in leukemia/lymphoma genetics, but IGKJ1 itself is not a direct disease-causing entity or target
05

Safety considerations

Not applicable. Since it is not a drug target, there are no safety concerns specifically associated with IGKJ1.
06

Interacting drugs

None. There are no drugs known to interact directly with IGKJ1
07

Biomarkers

None currently used. Immunoglobulin gene rearrangements (including IGKJ segments) are sometimes used to assess B cell clonality in leukemias/lymphomas, but IGKJ1 specifically is not a standardized biomarker

Beyond the preview

Go deeper on Immunoglobulin kappa joining 1 (IGKJ1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa joining 1 (IGKJ1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call